Zoetis Toekomstige groei
Future criteriumcontroles 2/6
Zoetis zal naar verwachting groeien in winst en omzet met respectievelijk 9.9% en 5.8% per jaar. De winst per aandeel zal naar verwachting groeien met 10.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 45.9% zijn.
Belangrijke informatie
9.9%
Groei van de winst
10.6%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 23.8% |
Inkomstengroei | 5.8% |
Toekomstig rendement op eigen vermogen | 45.9% |
Dekking van analisten | Good |
Laatst bijgewerkt | 12 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Nov 18Zoetis (NYSE:ZTS) Has A Pretty Healthy Balance Sheet
Oct 26Zoetis: A Solid Choice For The Young Dividend Growth Investor
Oct 09Do Zoetis' (NYSE:ZTS) Earnings Warrant Your Attention?
Oct 08Zoetis: Investing In Pet Health And Portfolio Wealth
Sep 26Are Investors Undervaluing Zoetis Inc. (NYSE:ZTS) By 23%?
Sep 20There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price
Aug 30Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Jul 16Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Jul 03Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
Jun 11A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Jun 10Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth
May 23Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
May 22The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 04Zoetis: Long-Term Buy Despite Safety Concerns
May 03Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit
Apr 12Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Mar 03Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E
Jan 01Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Dec 06Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Nov 18Zoetis: High-Quality Compounder With A Reasonable Price After Earnings
Nov 09Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
Oct 26Zoetis Is An Impressive Healthcare Compounder
Sep 26Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 10,386 | 3,034 | 2,957 | 3,420 | 14 |
12/31/2025 | 9,728 | 2,719 | 2,630 | 3,165 | 15 |
12/31/2024 | 9,262 | 2,461 | 2,219 | 2,712 | 12 |
9/30/2024 | 9,152 | 2,430 | 2,308 | 2,945 | N/A |
6/30/2024 | 8,915 | 2,344 | 2,103 | 2,718 | N/A |
3/31/2024 | 8,734 | 2,391 | 1,750 | 2,399 | N/A |
12/31/2023 | 8,544 | 2,344 | 1,621 | 2,353 | N/A |
9/30/2023 | 8,371 | 2,280 | 1,492 | 2,197 | N/A |
6/30/2023 | 8,222 | 2,213 | 1,285 | 1,999 | N/A |
3/31/2023 | 8,094 | 2,071 | 1,458 | 2,152 | N/A |
12/31/2022 | 8,080 | 2,114 | 1,326 | 1,912 | N/A |
9/30/2022 | 8,007 | 2,067 | 1,267 | 1,850 | N/A |
6/30/2022 | 7,995 | 2,090 | 1,429 | 1,977 | N/A |
3/31/2022 | 7,891 | 2,073 | 1,607 | 2,122 | N/A |
12/31/2021 | 7,776 | 2,037 | 1,736 | 2,213 | N/A |
9/30/2021 | 7,616 | 1,982 | 1,791 | 2,252 | N/A |
6/30/2021 | 7,412 | 1,909 | 1,702 | 2,161 | N/A |
3/31/2021 | 7,012 | 1,774 | 1,682 | 2,118 | N/A |
12/31/2020 | 6,675 | 1,638 | 1,673 | 2,126 | N/A |
9/30/2020 | 6,542 | 1,663 | 1,523 | 1,990 | N/A |
6/30/2020 | 6,340 | 1,617 | 1,456 | 1,934 | N/A |
3/31/2020 | 6,339 | 1,611 | 1,323 | 1,814 | N/A |
12/31/2019 | 6,260 | 1,500 | 1,335 | 1,795 | N/A |
9/30/2019 | 6,150 | 1,461 | 1,365 | 1,797 | N/A |
6/30/2019 | 6,046 | 1,375 | 1,463 | 1,841 | N/A |
3/31/2019 | 5,914 | 1,388 | 1,442 | 1,790 | N/A |
12/31/2018 | 5,825 | 1,428 | 1,452 | 1,790 | N/A |
9/30/2018 | 5,721 | 1,164 | 1,531 | 1,814 | N/A |
6/30/2018 | 5,588 | 1,115 | N/A | 1,703 | N/A |
3/31/2018 | 5,442 | 978 | N/A | 1,616 | N/A |
12/31/2017 | 5,307 | 864 | N/A | 1,346 | N/A |
10/1/2017 | 5,124 | 937 | N/A | 1,024 | N/A |
7/2/2017 | 5,018 | 878 | N/A | 824 | N/A |
4/2/2017 | 4,957 | 855 | N/A | 781 | N/A |
12/31/2016 | 4,888 | 821 | N/A | 713 | N/A |
10/2/2016 | 4,885 | 689 | N/A | 705 | N/A |
7/3/2016 | 4,858 | 639 | N/A | 670 | N/A |
4/3/2016 | 4,825 | 378 | N/A | 655 | N/A |
12/31/2015 | 4,765 | 339 | N/A | 664 | N/A |
9/27/2015 | 4,811 | 443 | N/A | 773 | N/A |
6/28/2015 | 4,807 | 420 | N/A | 672 | N/A |
3/29/2015 | 4,790 | 593 | N/A | 709 | N/A |
12/31/2014 | 4,785 | 583 | N/A | 626 | N/A |
9/28/2014 | 4,719 | 562 | N/A | 537 | N/A |
6/29/2014 | 4,612 | 527 | N/A | 548 | N/A |
3/30/2014 | 4,568 | 519 | N/A | 377 | N/A |
12/31/2013 | 4,561 | 504 | N/A | 681 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei ZTS ( 9.9% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van ZTS ( 9.9% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van ZTS zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van ZTS ( 5.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van ZTS ( 5.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen ZTS zal naar verwachting over 3 jaar zeer hoog zijn ( 45.9 %).